Listed

Eledon Pharmaceuticals, Inc.: Form 10-Q for the period ended Sep 30, 2020

Filed with the SEC on Nov 16, 2020 and accepted by EDGAR at Nov 16, 2020, 17:02 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2020-09-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Research and development3 months2020-07-01 to 2020-09-30$615.0kus-gaap:ResearchAndDevelopmentExpense
Research and development9 months2020-01-01 to 2020-09-30$3.1mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2020-07-01 to 2020-09-30−$6.1mus-gaap:OperatingIncomeLoss
Operating income9 months2020-01-01 to 2020-09-30−$12.1mus-gaap:OperatingIncomeLoss
Net income3 months2020-07-01 to 2020-09-30−$6.1mus-gaap:NetIncomeLoss
Net income9 months2020-01-01 to 2020-09-30−$16.9mus-gaap:NetIncomeLoss
Diluted EPS3 months2020-07-01 to 2020-09-30−$5.51us-gaap:EarningsPerShareBasicAndDiluted
Diluted EPS9 months2020-01-01 to 2020-09-30−$16.81us-gaap:EarningsPerShareBasicAndDiluted
Operating cash flow9 months2020-01-01 to 2020-09-30−$5.8mus-gaap:NetCashProvidedByUsedInOperatingActivities
Cash and equivalentsAt period end2020-09-30$114.5mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2020-09-30$115.1mus-gaap:AssetsCurrent
Total assetsAt period end2020-09-30$192.6mus-gaap:Assets
Current liabilitiesAt period end2020-09-30$6.1mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2020-09-30$6.1mus-gaap:Liabilities
Shareholders' equityAt period end2020-09-30$21.5mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001564590-20-054210. Last ingested by Listed: Nov 13, 2026, 16:16 ET. Listed shows no prices and gives no investment advice.